Jaswant S. Gidda

Anagin, Inc. develops targeted therapies for pathologies associated with disrupted synaptic plasticity in the central nervous system leading to psychiatric diseases. It targeted diseases such as post traumatic stress disorder (PTSD), traumatic brain injury (TBI), depression, neuropathic pain, Alzheimer’s disease and Parkinson’s disease. The company was founded by Anatha Shekhar and Yvonne Lai in 2013 and is headquartered in Indianapolis, IN.

Naurex, Inc. operates as a clinical-stage company, which develops therapies. The firm offers therapies for depression and other disorders in the central nervous system based on a mechanism of action for modulating the NMDA receptor (NMDAR). It offers a line of chemical drug classes, such as glycine-site functional partial agonists, which modulate the receptor in a different way than existing NMDAR agents. The firm provides GLYX-13, an NRX-1050 small molecule series and additional compounds for treatment-resistant depression. The company was founded by Joseph R. Moskal in 2006 and is headquartered in Evanston, IL.

Marcadia Biotech, Inc. develops therapeutic products for diabetes and obesity. It is a biopharmaceutical company focuses on developing a broad portfolio of drug candidates for treatment of diabetes and obesity. The company was founded in 2005 and is headquartered in Carmel, IN.